Ill. Admin. Code tit. 77, § 661.340 - Cystic Fibrosis (CF)
a) Interpretation
of Results. Although the majority of infants affected by CF will be identified
by this screening, due to genetic variabilities and variations in health
status, specimen quality, and timing of specimen collection, not all infants
affected by the disorder may be identified. As with any laboratory test, false
positive and false negative results are possible. Newborn screening test
results are insufficient information on which to base diagnosis or treatment.
1) CF is indicated by elevated neonatal
levels of immunoreactive trypsinogen (IRT) that can be detected in dried blood
spots. The normal IRT range shall be established using accepted statistical
techniques (for example, as described by the Association of Public Health
Laboratories, see Section
660.20).
2) When elevated levels of IRT are detected,
testing by genetic mutation analysis shall be performed as part of the newborn
screen, to decrease false positive results. As there are over 1,000 mutations
in the CF transmembrane conductance regulator (CFTR) gene, testing will yield
only 90 to 95 percent sensitivity.
3) When IRT levels and/or mutation analysis
are found to be abnormal indicating the possibility of CF, the Department will
recommend referral of the newborn to a designated medical specialist for
appropriate definitive testing and diagnostic studies.
b) Designation of Medical Specialist. In
addition to the minimum qualifications set out in Section
661.230, medical specialists
designated by the Department to follow-up on a screen positive for CF shall
possess certification by the American Board of Pediatrics in Pediatric
Pulmonology or Pediatric Gastroenterology. CF medical specialists should
provide the following: prompt access to quantitative pilocarpine iontophoresis
sweat chloride testing in a laboratory that meets all CLSI standards; a
multidisciplinary approach to care, including the availability of genetic
counselors, dietitians, respiratory therapists and social workers; and access
to microbiology laboratories that use CF-specific protocols for detection of
respiratory tract infection.
c)
Diagnosis and Treatment. Medical management by a designated medical specialist
is highly recommended. Prompt evaluation of exocrine pancreatic status coupled
with nutritional counseling is recommended after diagnostic confirmation. Close
follow-up by a medical specialist is recommended to monitor and treat changes
in nutrition and respiratory infection status.
Notes
State regulations are updated quarterly; we currently have two versions available. Below is a comparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare.
No prior version found.